Related Experiment Video
Updated: Mar 30, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis
Lucheng Zhu1,2, Saisai Jing2,3, Bing Wang2,3
1Affiliated Hangzhou Hospital of Nanjing Medical University, No.261, Huansha Road, Shangcheng District, Hangzhou, 310006, People's Republic of China.
Abstract:
Anti-PD-1/PD-L1 antibodies showed satisfactory efficacy in treating non-small-cell lung cancer. We conducted this meta-analysis to explore the advantage subtypes and best therapeutic modalities of Anti-PD-1/PD-L1 therapy on NSCLC. A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and the Cochrane Library. The pooled ORR, 6-month progression-free survival rate (PFSR6m), and 1-year overall survival rate (OSR1y) were calculated and compared. 15 trials were included in this meta-analysis. Our analyses demonstrated the pooled ORR of 1st line and 2nd or more line anti-PD-1/PD-L1 therapy were 36.5% (21.9-51.0%) and 17.0% (14.3-19.7%), respectively. While the difference was significant (Z = 3.31, p < 0.001). The pooled ORR for non-squamous and squamous cell lung cancer were 18.5% (16.0-21.1%) and 17.9% (14.4-21.5%), respectively. The difference was not significant (Z = 0.27, p = 0.791). The pooled ORR for PD-L1 positive and negative patients were 29.6% (21.6-37.6%) and 13.5% (10.6-16.3%), respectively. The difference was significant (Z = 4.39, p < 0.001). The PFSR6m for PD-L1 positive and negative NSCLC were 50.0% (40.5-62.3%) and 27.0% (19.2-34.7%). The difference was significant (Z = 3.72, p < 0.001). The OSR1y for PD-L1 positive and negative NSCLC were 66.8% (44.8%-88.9%) and 54.0% (32.6-75.3%). The difference was not significant (Z = 0.77, p = 0.441). Anti-PD-1/PD-L1 antibody can serve as a promising treatment option for NSCLC. Patients with positive PD-L1 expression may benefit more from anti-PD-1/PD-L1 therapy. 1st-line anti-PD-1/PD-L1 therapy can be chosen as the best modality. Squamous cell lung cancer also benefit from anti-PD-1/PD-L1 therapy.
Insights
Anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapies show efficacy in non-small-cell lung cancer (NSCLC). Patients with positive PD-L1 expression and those receiving first-line treatment benefit most from these immunotherapies.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
- Anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibodies have emerged as a significant therapeutic strategy for NSCLC.
- Optimal patient selection and treatment sequencing are crucial for maximizing the benefits of these immunotherapies.
Purpose of the Study:
- To conduct a quantitative meta-analysis evaluating the efficacy of anti-PD-1/PD-L1 therapies in NSCLC.
- To identify patient subtypes and therapeutic modalities that yield superior outcomes.
- To compare treatment effectiveness across different lines of therapy and histological subtypes.
Main Methods:
- Systematic literature search of PubMed, Web of Science, and Cochrane Library databases.
- Inclusion of 15 relevant clinical trials for quantitative meta-analysis.
- Calculation and comparison of pooled objective response rate (ORR), 6-month progression-free survival rate (PFSR6m), and 1-year overall survival rate (OSR1y).
Main Results:
- First-line anti-PD-1/PD-L1 therapy demonstrated a significantly higher pooled ORR (36.5%) compared to second-line or later (17.0%).
- Patients with positive PD-L1 expression showed significantly higher pooled ORR (29.6%) and PFSR6m (50.0%) than PD-L1 negative patients.
- No significant difference in ORR was observed between squamous and non-squamous NSCLC, suggesting benefit for both subtypes.
Conclusions:
- Anti-PD-1/PD-L1 antibodies represent a promising treatment option for NSCLC patients.
- Positive PD-L1 expression is a strong predictive biomarker for enhanced response to anti-PD-1/PD-L1 therapy.
- First-line administration of anti-PD-1/PD-L1 therapy is the optimal modality, and squamous cell lung cancer patients also benefit from this treatment approach.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
